230. Alveolar hypoventilation syndrome Clinical trials / Disease details
Clinical trials : 6 / Drugs : 7 - (DrugBank : 4) / Drug target genes : 16 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01500473 (ClinicalTrials.gov) | February 2012 | 22/12/2011 | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome | Congenital Central Hypoventilation Syndrome | Drug: Desogestrel | Children's Hospital Los Angeles | NULL | Not yet recruiting | 16 Years | 50 Years | Female | 8 | N/A | United States |
| 2 | NCT01243697 (ClinicalTrials.gov) | April 2011 | 17/11/2010 | Assessment of Desogestrel in Ondine Syndrome | Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome | Ondine Syndrome | Drug: desogestrel | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 10 Years | 60 Years | Female | 6 | Phase 2/Phase 3 | France |
| 3 | EUCTR2011-000989-35-FR (EUCTR) | 06/05/2011 | N/A | N/A - RESPIRONDINE | MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Cerazette Product Name: Cerazette INN or Proposed INN: Désogestrel | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | NA | Female: yes Male: no | Phase 2 | France |